drugset / Trial / NCT00540501

A Study to Evaluate Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Subjects

NCT00540501

Phase 1 Withdrawn GlaxoSmithKline
RandomizedSingle-groupOpen-labelTreatment

Summary

This study is a 4 period study to see if there is any interaction between Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Thai Adult Subjects

Timeline

Start
2007-10
Primary completion
2007-10
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Oseltamivir Small molecule 150 mg Oral
Subject Zanamivir Small molecule 50 mg Intravenous
Subject Zanamivir Small molecule 600 mg Intravenous

Indications

No indication recorded.